The results and conclusions of the work conducted by the Lymphoma Research Experts ecosystem are published in leading medical journals.
Lysa
2024_Prognostic Value of 18F-FDG PET Radiomics Features at Baseline in PET-Guided Consolidation Strategy in Diffuse Large B-Cell Lymphoma: A Machine-Learning Analysis from the GAINED Study
2024;65:156-162
Learn more
Lysa
2024_Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial☆
Annals of Oncology 2024;35:130-137
Learn more
Lysa
2024_Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma
JCO 2024;42:19-25
Learn more
Lysa
2024_Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
2024;625:778-787
Learn more
Lysa
2024_Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma—Final Analysis
2024;16:2672
Learn more
Lysa
2024_Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18F-FDG PET/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma
2024;49:e1
Learn more
Lysa
2023_Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy
Haematologica 2023;108:3433-3437
Learn more
Lysa
2023_Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX
Clin Transl Sci 2023;16:2744-2755
Learn more
Lysa
2023_Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
Blood Adv 2023;7:6589-6598
Learn more
Lysa
2023_Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.
Blood 2023;142:3112
Learn more
Lysa
2023_CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
Blood 2023;142:1543-1555
Learn more
Lysa
2023_Validation of the ΔSUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial
J Nucl Med 2023;64:1706-1711
Learn more
Lysa
2023_Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial
Sci Rep 2023;13:18177
Learn more
Lysa
2023_Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Nat Med 2023;29:2593-2601
Learn more
Lysa
2023_Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)
Leukemia 2023;37:1887-1894
Learn more
Lysa
2023_Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
Lancet Haematol 2023;10:e624-e632
Learn more
Lysa
2023_Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany
Br J Haematol 2023;202:771-775
Learn more
Lysa
2023_Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen
Br J Haematol 2023;202:686-689
Learn more
Lysa
2023_Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)
Eur J Cancer 2023;189:112909
Learn more
Lysa
2023_Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group
Blood Adv 2023;7:3735-3738
Learn more
Lysa
2023_Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
J Clin Oncol 2023;41:3523-3533
Learn more
Lysa
2023_Work and education interruption in long-term Hodgkin lymphoma survivors: an analysis among patients from nine EORTC-LYSA trials
Acta Oncol 2023;62:744-752
Learn more
Lysa
2023_Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA
Br J Haematol 2023;202:379-383
Learn more
Lysa
2023_The Negative Influence of Baseline Cell-free DNA on Long-term Survival in DLBCL Depends on Frontline Treatment Intensity
Clin Cancer Res 2023;29:2280-2290
Learn more